DAVID GREENBLUM: Open Payments
NPI 1467462713 · KENSINGTON, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,679 in 77 payments from 12 companies in 2025. Trend: 2023 $7,756 · 2024 $12,525 · 2025 $1,679
Food & beverage: $1,679
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 18 | $401 |
| Neurocrine BioSciences, Inc. | 8 | $304 |
| Teva Pharmaceuticals USA, Inc. | 11 | $179 |
| Otsuka America Pharmaceutical, Inc. | 7 | $158 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $141 |
| ABBVIE INC. | 6 | $124 |
| Supernus Pharmaceuticals, Inc. | 10 | $118 |
| Indivior Inc. | 4 | $105 |
| Braeburn Inc. | 2 | $60 |
| Janssen Pharmaceuticals, Inc | 2 | $54 |
Products named: COBENFY, INGREZZA, CAPLYTA, UZEDY, VRAYLAR, Qelbree, SUBLOCADE, ABILIFY ASIMTUFII.
Industry payments across MD — which companies pay providers there.
